The SYNERGY-NASH trial, for example, demonstrated that tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, led to the resolution of MASH and weight reduction in patients with T2DM [91]. Here, GIP is linked to metabolic dysfunction-associated steatohepatitis.